Omalizumab treats multi-food allergy better than oral immunotherapy NIH News Release

High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab. High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab. Read More NIH News Release

Leave a Comment

Your email address will not be published. Required fields are marked *